MEFV and arthritic joint disease: We divided this large cohort into training and validation cohorts and a score was developed in the training cohort including the independent predictors of colchicine resistance as the age of symptom onset ≤3 years, attack frequency before diagnosis ≥1 attack/month, arthritis, chest pain and homozygosity or compound heterozygosity for exon 10 MEFV mutations.